摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-Methyl-2H-pyrazol-3-yl)-[2-(pyridin-3-ylmethylamino)-quinazolin-4-yl]-amin

中文名称
——
中文别名
——
英文名称
(5-Methyl-2H-pyrazol-3-yl)-[2-(pyridin-3-ylmethylamino)-quinazolin-4-yl]-amin
英文别名
4-N-(5-methyl-1H-pyrazol-3-yl)-2-N-(pyridin-3-ylmethyl)quinazoline-2,4-diamine
(5-Methyl-2H-pyrazol-3-yl)-[2-(pyridin-3-ylmethylamino)-quinazolin-4-yl]-amin化学式
CAS
——
化学式
C18H17N7
mdl
——
分子量
331.38
InChiKey
RCBHCMLALOQPFS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    91.4
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • Pyrazole compounds useful as protein kinase inhibitors
    申请人:Bebbington David
    公开号:US20050038023A1
    公开(公告)日:2005-02-17
    This invention describes novel pyrazole compounds of formula IIIa: wherein R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x , R y , R 2 ; and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    这项发明描述了公式IIIa的新型吡唑化合物:其中R1是T-Ring D,其中环D是选择自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环环;Rx、Ry、R2和R2'如规范中描述。这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂,用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
  • Pyrazole compounds useful as protein kinase inhititors
    申请人:——
    公开号:US20030004161A1
    公开(公告)日:2003-01-02
    This invention describes novel pyrazole compounds of formula I′: 1 wherein Q′ is —O—, —C(R 6′ ) 2 —, 1,2-cyclopropanediyl, 1,2-cyclobutanediyl, or 1,3-cyclopropanediyl, and R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 or L-Z-R 3 or R x and R y are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R 2 and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    这项发明描述了一种新颖的吡唑类化合物,化学式为I′:1其中Q′为—O—、—C(R6′)2—、1,2-环丙烷二基、1,2-环丁烷二基或1,3-环丙烷二基,R1为T-Ring D,其中Ring D为从芳香族、杂芳基、杂环基或碳环基中选择的5-7成员单环或8-10成员双环;Rx和Ry分别独立选择自T-R3或L-Z-R3或Rx和Ry与它们之间的原子结合形成融合、不饱和或部分不饱和、含有0-3个杂原子的5-7成员环;R2和R2′如规范中描述。这些化合物可用作蛋白激酶抑制剂,特别是作为Aurora-2和GSK-3的抑制剂,用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
  • PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    申请人:Bebbington David
    公开号:US20090312543A1
    公开(公告)日:2009-12-17
    This invention describes novel pyrazole compounds of formula IIIa: wherein R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x , R y , R 2 , and R 2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    本发明描述了式IIIa的新型吡唑化合物: 其中R1是T-Ring D,其中环D是5-7成员单环或8-10成员双环,选自芳基,杂芳基,杂环基或碳环基;Rx,Ry,R2和R2'如说明书所述。该化合物可用作蛋白激酶抑制剂,特别是用于抑制Aurora-2和GSK-3,治疗癌症,糖尿病和阿尔茨海默病等疾病。
  • Crystal structure of aurora-2 protein and binding pockets thereof
    申请人:Cheetham Graham
    公开号:US20050143402A1
    公开(公告)日:2005-06-30
    The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof.
    本发明提供了包含 Aurora-2 或其同源物结合口袋的晶体分子或分子复合物。本发明还提供了包含 Aurora-2 的晶体。本发明还涉及一种计算机,该计算机包含一个用 Aurora-2 结合口袋的结构坐标编码的数据存储介质,以及使用计算机评估化合物与分子或分子复合物结合能力的方法。本发明还提供了使用结构坐标解决同源蛋白质或蛋白质复合物结构的方法。此外,本发明还提供了利用结构坐标筛选和设计与 Aurora-2 或其同源物结合的化合物(包括抑制性化合物)的方法。
  • CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF
    申请人:VERTEX PHARMACEUTICALS INCORPORATED
    公开号:EP1549318A2
    公开(公告)日:2005-07-06
查看更多